Abstract
We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.
Original language | English |
---|---|
Article number | 162 |
Journal | BMC Neurology |
Volume | 18 |
DOIs | |
Publication status | Published - 3 Oct 2018 |
Bibliographical note
This work is part of a larger report commissioned by the NIHR HTA Programme as project number ID809. Aileen Clarke and G.J. Melendez-Torres are partly supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University Hospitals Birmingham NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, NICE or the Department of Health and Social Care.Keywords
- multiple sclerosis
- clinically isolated syndrome
- beta-interferon
- glatiramer acetate
- systematic review
- economic evaluation